Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment
Clinical and Translational Science · 2025
DOI: 10.1111/cts.70265 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Olivier Schueller und 6 weiteren Autor:innen. Beteiligte Einrichtung: Kadmon, a Sanofi Company, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Liver Diseases. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Belumosudil, an orally administered Rho‐associated coiled‐coil–containing protein kinase 2 selective inhibitor drug for treatment of chronic graft‐versus‐host disease (GVHD), is predominantly eliminated via the liver. This phase 1, open‐label, non‐randomized, parallel‐group study (NCT04166942) evaluated belumosudil pharmacokinetics and safety after a single 200‐mg dose in participants with mild, moderate, or severe hepatic impairment (Child‐Pugh classification), matched with healthy participants with normal hepatic function. M1 and M2 metabolites were also assessed. Geometric least squares mean (GLSM) ratios (90% confidence intervals [CI]) for belumosudil area under the plasma concentration‐time curve (AUC) from time 0 to the time to infinity (AUC 0‐∞ ), AUC to the time of last measurable concentration (AUC 0− t ), and maximum concentration ( C max ) were 1.36 (0.83–2.21), 1.48 (0.96–2.28), and 1.20 (0.91–1.58), respectively, for the mild impairment group, and 1.51 (0.98–2.33), 1.50 (0.97–2.31), and 0.94 (0.60–1.48), respectively, for the moderate impairment group. Severe hepatic impairment markedly increased belumosudil AUC 0–∞ and AUC 0– t but had no apparent effect on C max ; GLSM ratios (90% CI) were 4.21 (2.20–8.06), 3.23 (1.53–6.81), and 1.32 (0.90–1.96), respectively. A post hoc analysis was conducted using the National Cancer Institute‐Organ Dysfunction Working Group (NCI‐ODWG) classification for hepatic impairment. Assessment by NCI‐ODWG criteria, compared with Child‐Pugh criteria, revealed a higher range of exposure in participants with moderate hepatic impairment. Belumosudil can be taken by patients with mild hepatic impairment without dose adjustment; avoid use in patients with moderate hepatic impairment (Child‐Pugh B) or severe hepatic impairment (Child‐Pugh C) without liver GVHD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kadmon, a Sanofi Company, Cambridge, Massachusetts, USA.
- Sanofi, Vitry-Sur-Seine, France.
- Nuventra, Inc., Durham, North Carolina, USA.
- Sanofi, Ghent, Belgium.
- Sanofi, Frankfurt, Germany.
- Sanofi, Cambridge, Massachusetts, USA.
ORCID-Profile: Olivier Schueller, Felix Beck
Zitieren
APA
Schueller, O., Esposito, V., Lohmer, L., Beck, F., Teichert, L., Patel, J., & Sahi, J. (2025). Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment. Clinical and Translational Science. https://doi.org/10.1111/cts.70265
Vancouver
Schueller O, Esposito V, Lohmer L, Beck F, Teichert L, Patel J, et al. Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment. Clinical and Translational Science. 2025. doi:10.1111/cts.70265
BibTeX
@article{Schueller2025,
author = {Schueller, Olivier and Esposito, Virginie and Lohmer, Lauren and Beck, Felix and Teichert, Lenore and Patel, Jeegar and Sahi, Jasminder},
title = {Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment},
journal = {Clinical and Translational Science},
year = {2025},
doi = {10.1111/cts.70265}
}
EUVIMED